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Commentary
Braak Staging in Mouse Models of Alzheimer’s
Disease
Ivica Granic,* Marcelo F. Masman,†
Paul G.M. Luiten,†‡ and Ulrich L.M. Eisel†
From the Department of Molecular Animal Physiology,* Donders
Center for Neuroscience and the Nijmegen Center for Molecular
Life Sciences (NCMLS), Radboud University, Nijmegen; and the
Departments of Molecular Neurobiology,† and Biological
Psychiatry,‡ University of Groningen, Haren, The Netherlands
Alzheimer’s disease (AD) is a heterogeneous multifacto-
rial disease and is the most common progressive and
aging-related neurodegenerative disorder. The major neu-
ropathological features of AD are extracellular amyloid
plaques and intracellular neurofibrillary tangles (NFTs), con-
sisting of, respectively, aggregated amyloid- peptide (A)
and hyperphosphorylated microtubule-associated protein
Tau (MAPT). These histopathological lesions are mainly
present in the hippocampus and the cerebral cortex, two
large forebrain domains that are crucial for acquisition
and storage of memory and other higher cognitive func-
tions. The characteristic pathology eventually leads to the
typical clinical symptoms associated with AD, such as
general cognitive decline, dramatic memory loss, and
severe personality changes. The most important risk fac-
tor for developing AD is advanced age. After the age of
65, the prevalence of AD in Western societies is forecast
to double every five years (http://www.alz.org, last ac-
cessed August 15, 2010). By the age of 80, the number of
patients suffering from AD is calculated to increase up to
40%.
An article in this issue of the American Journal of Pa-
thology by David E. Hurtado and colleagues1 reports on
a new mouse model of AD, possessing A and MAPT
pathologies, which was created by the crossing of PS19
and PDAPP transgenic mice. These mice were charac-
terized and staged for the occurrence of the NFT pathol-
ogy in a spatiotemporal staging paradigm that is compa-
rable to the Braak pathological stages of NFT in the
human AD brain. Here, we provide a short survey of the
mouse models that led to the article by Hurtado et al.
Furthermore, we tried to highlight the importance and
necessity of critical and systematic analyses, such as
Braak-like staging in AD mouse models.
Even a century after the first description of the disease
by Alois Alzheimer in 1907, the etiology of the disease is
still poorly understood. However, several lines of evi-
dence point to A as the major factor in the pathogenesis
of AD. The amyloid cascade hypothesis proposes that
the A peptides form toxic assemblies that initiate several
processes, leading to neuronal dysfunction and eventu-
ally large-scale cell death.2 The only definitive diagnosis
of AD is made postmortem, the pathological hallmarks
being extracellular amyloid plaques comprising A,
which is a cleavage product of the amyloid precursor
protein (APP), and intracellular NFTs comprising hyper-
phosphorylated MAPT. This pathology shows a distinct
spatiotemporal pattern, initially affecting areas of the tem-
poral cortex, in particular the trans-entorhinal region, be-
fore extending to the hippocampus and certain other
cortical zones. During the later disease stages, a more
widespread pathology can be observed in frontal and
temporal cortical areas and limbic regions.3 By pro-
cesses that are not fully understood, the accumulation of
A and NFTs leads to injury of synaptic functioning be-
tween nerve cells and eventually produces massive local
neurodegeneration, which ultimately accounts for the
clinical signs of this disease.
The identification of genetic factors contributing to this
disease has accelerated research on the biology of APP
and MAPT, which has led to the generation of several
transgenic mouse models that display some characteris-
tic neuropathological features of AD, such as an age-
dependent formation of amyloid plaques consisting of A
peptides.4,5 These models have been very important for
our understanding of the complex pathogenic mecha-
nism underlying AD.
Current transgenic models of AD rely almost exclu-
sively on information gathered from inherited forms of the
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disease, which are far less common than sporadic forms,
but are indistinguishable from a clinical and histopatholog-
ical point of view. Despite the large quantity of transgenic
AD mouse models in general, there is no ideal “complete”
mouse model that incorporates all aspects of AD.
In the early 1990s, the first transgenic mice were gen-
erated by inserting the entire human APP gene into the
mouse brain.6–9 Despite the successful expression of the
APP gene product in the brain, these mice showed only
very mild neuropathological changes, with only a few or
no A deposits. The lack of plaques in these transgenic
mice was generally attributed to the insufficient expres-
sion of the transgene, the absence of mutations in the
transgene, the genetic background of the mice, or to
other unknown factors inherited by the mouse brain com-
pared to the human.
The first mutant APP mouse model with robust plaque
pathology was the PDAPP transgenic mouse. These mice
express a human APP cDNA with the Indiana mutation
V717F. Hemizygous mice begin to develop plaque pa-
thology at the age of 6–9 months. These mice do not
show NFT pathology and no neuronal loss but do show
loss of synapses.10 Another mouse line with plaque pa-
thology is the Tg2576 line, which expresses the mutant
APP, which bears the Swedish mutation under the control
of the hamster prion promoter. These mice develop
plaque pathology from the age of 9 months on with cog-
nitive deficits but without neuronal loss or NFT patholo-
gy.11 Like the Tg2576 mice, the APP23 mice also express
mutant APP containing the Swedish mutation, but under
the control of the Thy-1 promoter.12 This genetically ma-
nipulated mouse line shows prominent cerebrovascular
amyloid pathology, amyloid plaques from the age of six
months on, and some neuronal loss in the hippocampus.
However, also in this transgenic mouse line, no NFT
pathology has been observed.
Mice expressing either the wild-type or mutated pres-
inilin-1 gene fail to develop significant AD-like pathology
despite having high levels of A.13–15 However, when
mutant presenilin-1 mice are crossed with Tg2576 mice,
A aggregation into plaques is greatly accelerated.16
The absence of neuronal loss in most APP models sug-
gests that physiological A accumulation and subse-
quent plaque formation are not sufficient to cause rapid
neuronal cell death in vivo. This in turn suggests that A
species alone are unlikely to cause widespread neuronal
loss in the absence of major secondary pathogenic fac-
tors in human patients and is consistent with human
neuropathological studies that show no correlation be-
tween overall levels of amyloid deposition and clinical
progression of AD. One possible explanation may be the
absence of NFT formation in the APP models and, hence,
the missing link to massive neuronal cell loss in AD.
This view led to the development of several mutant
mouse models with the characteristic Tau pathology to
examine the particular role of MAPT in AD.
The first transgenic animal with marked tangle pathol-
ogy and cell loss was the JNPL3 mouse, which expresses
MAPT with the P301L mutation.17 This model could
clearly demonstrate that MAPT alone can cause cellular
damage and neuronal loss.
Htau transgenic mice express only human MAPT, be-
cause mouse MAPT was knocked out in this model.18
These mice accumulate hyperphosphorylated Tau at the
age of six months and develop NFT pathology within 15
months of age.
Another mouse model with progressive NFT pathology
and severe neuronal loss is the inducible MAPT trans-
genic line rTg4510.19,20 Abnormal MAPT pathology in
these animals can already be observed at one month of
age. Furthermore, these mice show cognitive deficits
from 2.5 months forward. Cognitive performance im-
proves if the transgene is turned off despite worsening
NFT pathology.
Because most of these mentioned models show only
one of the characteristic pathological features of AD, either
A or MAPT pathology, investigators began to cross mutant
APP and MAPT transgenic mouse lines to obtain a mouse
line with both pathological hallmarks of AD.
Such mice have significantly expanded our under-
standing of A and MAPT pathologies. For instance,
crossing the Tg2576 and the JNPL3 lines resulted in mice
(TAPP) with increased MAPT forebrain pathology com-
pared with JNPL3 mice, suggesting that either APP or A
can influence downstream MAPT pathology.21
Another prominent transgenic mouse line that accu-
mulates both intraneuronal A, extracellular amyloid
plaques, and NFT lesions in an age-dependent fashion is
the triple transgenic mouse model (3xTg-AD),22 which
harbors preseniline-1 (M146V), APPswe, and MAPT
(P301L) transgenes. These mice develop age-dependent
synaptic dysfunction, including deficits of long-term po-
tentiation, and memory deficits that correlate with an
accumulation of intraneuronal A.23,24 Probably the main
observation obtained from this mouse model is that an
excess of A can elicit cognitive impairment even in the
absence of NFT or neuronal loss.
Because of variations in neuropathologies and behav-
iors between transgenic mouse models and human dis-
ease, as well as among different transgenic lines, it is
imperative to be cautious with comparing and interpret-
ing results. Therefore, a standardized and critical analy-
sis of information provided by genetic mouse models is
needed to warrant quality and valuable preclinical re-
search on AD neuropathology.
In the article by David E. Hurtado1 and co-workers in
this issue of the American Journal of Pathology, the authors
developed a new mouse model for AD, which possesses
A and MAPT pathologies, by crossing PS19 and PDAPP
Tg mice. These mice were characterized and staged for
the occurrence of NFT pathology in a spatiotemporal
staging paradigm comparable to the Braak pathological
stages of NFT in AD human brains. This approach of
MAPT pathology staging may help to explain the stereo-
typical manner in which the MAPT and A pathologies
appear, evolve, and spread over time with disease pro-
gression. Interestingly, their murine model of A and
MAPT pathologies shows a very similar sequence of
pathological progression of AD MAPT pathology as ob-
served in human AD patients. Furthermore, Hurtado and
colleagues demonstrate that the presence of A accel-
erates NFT formation and enhances MAPT pathology.
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They also show that MAPT pathology does not have the
same accelerating effect on A pathology.
Their findings substantiate the amyloid cascade hy-
pothesis of AD. According to this hypothesis, an accu-
mulation of A is the primary factor of AD pathogenesis.
The Tau-related pathology of the disease process, in-
cluding formation of NFTs, is proposed to result from an
imbalance of A production and A clearance. The data
presented in the study by Hurtado et al is in line with data
from studies of 3xTg mice, which support the idea that
MAPT pathology is a downstream event of A accumu-
lation. A recent study by Tomiyama et al demonstrated
that A oligomers are sufficient to cause synaptic alter-
ation in addition to abnormal MAPT phosphorylation, glial
activation, and neuronal loss in vivo.25 Taken together,
these findings reported here are important for our further
understanding of the mechanisms underlying the onset
as well as the progression of AD. However, to date, no
transgenic mouse line has been able to represent all
aspects of human AD pathology. This might be due to the
limitations of rodent systems to reproduce a complex
human disorder, such as AD, in which the pathogenesis
usually takes several decades to manifest and primarily
involves higher cognitive functions. Additional spatiotempo-
ral staging of other histopathological features of AD, for
example glial activation, cytokine release, or vascular
changes such as reduction of cerebral blood flow, would
provide additional valuable insights into the mechanisms of
AD pathology for both basic and translational research.
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